Dr. Ronald D. Ennis, MD

Dr. Ennis practices at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health.

Dr. Ennis' NPI, 1780668400, was assigned on December 6, 2005. Dr. Ennis graduated from Yale School of Medicine in 1990. Dr. Ennis holds New Jersey license 25MA09380900.

Dr. Ennis' primary practice is Robert Wood Johnson University Hospital, at One Robert Wood Johnson Place, New Brunswick, NJ 08901 in Middlesex County. The practice phone is (732) 828-3000. Dr. Ennis also practices at Robert Wood Johnson University Hospital - New Brunswick, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901.

Dr. Ennis' primary practice is Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health. Dr. Ennis is also affiliated with Mount Sinai West. The medical group on file is University Neuro-Ophthalmology Associates. Dmand AI also links Dr. Ennis to 5 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ennis practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Ennis' primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Ennis is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Ennis' licenses on file in 3 states: New Jersey, New York and Connecticut.

Dmand AI lists bladder cancer radiation, breast cancer radiation, cervical cancer radiation, prostate cancer radiation and uterine cancer radiation among the conditions Dr. Ennis treats.

CMS data shows 1,216 Medicare services from Dr. Ennis across 15 procedure codes in 2024, for 158 Medicare patients. Medicare paid $85,638 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 158 Medicare patients who saw Dr. Ennis in 2024. The largest group is 65 to 74, with 74 patients. 75% of them have cancer, and 75% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.41, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ennis' median patient age at 74, with 16% women.

In 2024, Dr. Ennis wrote 288 Medicare Part D claims for 62 patients. 80% of them were for generic drugs. CMS names the drug for 213 of them, across 6 drugs with 11 or more claims each, at $75,435 in total drug cost. In 2023, CMS named 215 claims across 6 drugs.

Dr. Ennis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ennis as offering telehealth.

Dmand AI links 56 papers to Dr. Ennis, published from 2011 to 2024. 2020 was the busiest year, with 4. The most frequent topics are Prostatic Neoplasms, Radiation Oncology and Brachytherapy. Dr. Ennis has published most often in Int J Radiat Oncol Biol Phys. Dr. Ennis' most frequent co-authors are Mitchell Clark Benson, MD, Lara Hathout and Matthew Pierre Deek, MD.

Dmand AI links Dr. Ennis to 3 clinical trials, 2 of them phase 1/2 studies. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Renal Cell. Beth Israel Medical Center sponsors the most, 2.

CMS Open Payments shows 23 general payments to Dr. Ennis from 8 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 44% of the total. Siemens Medical Solutions USA, Inc. paid the most, $2,211.

Dmand AI lists 1 award for Dr. Ennis.

Dr. Ennis graduated from Yale School of Medicine in 1990. Dr. Ennis is a member of ASTRO and ASCO.

Dr. Ennis is in network with 15 carriers, including Aetna, United Healthcare and Cigna. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.